NCT04791007View on ClinicalTrials.gov

OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 5, 2019

Primary Completion Date

April 6, 2020

Study Completion Date

August 31, 2020

Conditions
HIV Prevention
Interventions
DRUG

OB-002

vaginal or rectal administration

DRUG

Placebo

vaginal or rectal administration

Trial Locations (1)

05-410

BioVirtus Centrum Medyczne Sp. z o.o., Józefów

All Listed Sponsors
collaborator

Scope International AG

INDUSTRY

lead

Orion Biotechnology Polska Sp. z o.o.

INDUSTRY

NCT04791007 - OB-002H Gel Administered Vaginally and Rectally in HIV-1 Seronegative Adults | Biotech Hunter | Biotech Hunter